{"id": "chatcmpl-B2D22AYUxVyM7sguuVXbgpqezT042", "object": "chat.completion", "created": 1739866450, "model": "gpt-4o-mini-2024-07-18", "choices": [{"index": 0, "message": {"role": "assistant", "content": null, "function_call": {"name": "get_emergingissues", "arguments": "{\"issues\":[{\"name\":\"Supply Chain Constraints\",\"description\":\"Novo Nordisk is facing challenges in scaling up production to meet the rising demand for semaglutide, leading to restricted supplies.\",\"relevancy\":5},{\"name\":\"Market Competition for Obesity Treatments\",\"description\":\"The potential approval of Eli Lilly's Mounjaro as a weight-loss drug may intensify competition in the obesity treatment market.\",\"relevancy\":4},{\"name\":\"Wider Public Awareness of Obesity Treatments\",\"description\":\"Semaglutide has gained household recognition, suggesting a shift in public perception towards medical treatment of obesity and its acceptance.\",\"relevancy\":4},{\"name\":\"Healthcare System Adoption of New Treatments\",\"description\":\"The rapid adoption of semaglutide in health systems highlights the increasing focus on innovative drugs for obesity management.\",\"relevancy\":3},{\"name\":\"Investor Sentiment in Healthcare Sector\",\"description\":\"The soaring market value of Novo Nordisk reflects strong investor confidence in the growing obesity treatment market and related pharmaceuticals.\",\"relevancy\":4}]}"}, "refusal": null}, "logprobs": null, "finish_reason": "function_call"}], "usage": {"prompt_tokens": 715, "completion_tokens": 221, "total_tokens": 936, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_13eed4fce1"}